BioSpace News Archive

Can-Fite BioPharma Ltd. announced it will conduct a conference call with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson which achieved its primary and secondary efficacy endpoints, while showing continued safety.

Cytokinetics, Incorporated provided an update regarding the company’s clinical trials and business operations related to its response to the COVID-19 pandemic alongside its commitment to prioritize the safety, health and wellbeing of patients, their caregivers, healthcare providers, partners and employees.

OpGen, Inc. announced that total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that Walter Klemp, Chairman and Chief Executive Officer, will host a web-based conference call on April 16th at 4:30pm ET

Intact Vascular’s Tack Endovascular System is a First-of-its-Kind Vascular Implant for Optimized Balloon Angioplasty Outcomes in Challenging CLI Patient Population

Phase 1 clinical study in patients with refractory NSCLC expected to begin in Second Quarter 2020

Coherus BioSciences, Inc., announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Seattle’s AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkins Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia.

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today provided a clinical update on the impact of the COVID-19 pandemic on the status of NORSE 1 and NORSE 2, its ongoing registration clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab.

7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for 7HP349, a first-in-class, oral integrin activator that has the potential to augment antigen-specific immune responses.